1 Proteomic profiling of peripheral blood mononuclear cells reveals immune

dysregulation and metabolic alterations in kidney transplant recipients with 2 COVID-19

- 3
- 4
- Giuseppe G. F. Leite^{1*}, Mônica Braganca Sousa¹, Larissa de Oliveira C. P. Rodrigues¹, 5
- Milena Karina Colo Brunialti¹, José Medina-Pestana^{2,3}, Joe M. Butler⁴, Hessel Peters-6
- Sengers^{4,5}, Lúcio Reguião-Moura^{2,3}, Reinaldo Salomão^{1*} 7
- ¹ Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal 8 de São Paulo, São Paulo 04023-900, Brazil; 9
- ² Division of Nephrology, Escola Paulista de Medicina, Universidade Federal de São 10 Paulo, São Paulo 04038-031, Brazil; 11
- ³ Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04038-002, Brazil; 12
- ⁴ Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC, location 13 University of Amsterdam, Amsterdam, The Netherlands; 14
- ⁵ Department of Epidemiology and Data Science, Amsterdam UMC, location Vrije 15 Universiteit, Amsterdam, the Netherlands; 16
- 17

18 * Correspondence:

- Giuseppe G. F. Leite and Reinaldo Salomão, Division of Infectious Diseases, Escola 19
- Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04023-900, 20
- Brazil. Email: giuseppe.gianini@unifesp.br and rsalomao@unifesp.br 21

22	
23	
24	
25	
26	
27	
28	
29	
30	
31	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract 32

The emergence of the Coronavirus disease 2019 (COVID-19) pandemic in 2020 has 33 profoundly impacted global health systems, particularly affecting vulnerable 34 populations like kidney transplant recipients (KTRs). We prospectively collected blood 35 samples from 17 PCR-confirmed COVID-19 KTR patients and 10 non-COVID-19 36 KTRs between May and September 2020. Using tandem mass tag-based quantitative 37 proteomics, we characterized peripheral blood mononuclear cells (PBMCs) from KTRs 38 39 alongside plasma protein biomarkers and lymphocyte counts, followed by bioinformatics analyses. Our study revealed significant proteomic alterations within 40 PBMCs of SARS-CoV-2 infected KTRs, particularly in pathways associated with 41 42 glycolysis, glucose metabolism, and neutrophil degranulation. Additionally, we observed an altered immune response marked by elevated cytokines and 43 inflammatory mediators, coupled with decreased lymphocyte counts. Notably, patients 44 with acute kidney injury (AKI) exhibited worse outcomes, including higher rates of ICU 45 transfer and mechanical ventilation. Comparison of PBMC proteomic profiles between 46 AKI and non-AKI patients highlighted distinct immune-related pathways, with AKI 47 patients showing pronounced alterations in innate immune responses, particularly in 48 49 neutrophil degranulation. Moreover, our analysis unveiled a negative correlation between T cell counts and neutrophil degranulation, suggesting potential implications 50 for immune dysregulation in COVID-19. Our findings shed light on the complex 51 52 proteomic landscape and immune responses in COVID-19-infected KTRs, emphasizing the critical need for studies focused on this population, especially in 53 individuals with AKI. Furthermore, our observations provide valuable insights for 54 further exploration of therapeutic interventions targeting immune dysregulation 55 pathways in this vulnerable population. 56

Keywords: KTRs, PBMC, acute kidney injury, SARS-CoV-2, systems biology, mass 57 58 spectrometry

- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66

68 INTRODUCTION

The Coronavirus disease 2019 (COVID-19) pandemic, which emerged in 2020, rapidly became a global health crisis, profoundly affecting healthcare systems, economies, and overall quality of life [1, 2]. Prior to the achievement of widespread vaccination coverage, COVID-19 presented with a wide range of clinical manifestations, from asymptomatic or presymptomatic states to varying degrees of severity, including mild, moderate, severe, and, in some cases, life-threatening complications[3].

Individuals with compromised immune systems, especially those undergoing immunosuppressive therapy, were particularly vulnerable. Among these high-risk groups, kidney transplant recipients (KTRs) demonstrated notably higher case-fatality rates, even after vaccination [4, 5], and exhibited lower seroconversion rates following vaccination [6]. This elevated risk underscores the compounded vulnerabilities associated with immunosuppressive treatments and the presence of multiple comorbidities in these patients [7-9].

The cumulative number of comorbidities associated with an immune system 82 83 impairment has led to diverse responses to COVID-19 among KTRs compared with non-transplanted patients [7-9]. Investigating a panel of circulating cytokines and 84 vascular mediators in sequential samples, we previously demonstrated that both non-85 KTRs and KTRs infected with COVID-19 exhibited a similar transition from admission 86 to convalescent samples. However, the key mediators differentiating patients from 87 their respective controls (i.e., healthy volunteers and non-infected KTRs) were distinct. 88 For non-KTRs, the top differentiators were inflammatory cytokines, whereas for KTRs, 89 endothelial response patterns and levels of Neutrophil Gelatinase-Associated 90 91 Lipocalin (NGAL)[10], an early marker of acute kidney injury (AKI), were the most

significant. AKI, commonly observed in numerous systemic conditions [11], has been
linked to poor outcomes, a trend that persisted in COVID-19 patients. A multicenter
study involving 1,680 KTRs with COVID-19 revealed that the mortality rate was 36.0%
in those with AKI, compared to 19.1% in patients maintaining normal renal function,
highlighting renal function as a key predictor of survival in this population [12].

97 Recently, mass spectrometry (MS)-based proteomics, primarily focused on plasma, 98 serum, and urine, has emerged as a powerful tool to shed light on a broad spectrum 99 of dysregulated biological processes in KTRs with COVID-19 [13, 14]. However, the 100 influence of SARS-CoV-2 infection on peripheral blood mononuclear cells (PBMCs) in 101 KTRs remains a subject of ongoing investigation.

102 In this study, we employed a tandem mass tag (TMT)-based quantitative proteomic approach, coupled with bioinformatics analyses, to investigate altered proteins 103 associated with dysregulated pathways and biological processes in kidney transplant 104 recipients (KTRs) with COVID-19. We focused on patients with moderate to severe 105 illness admitted to hospital wards who presented with or without acute kidney injury 106 107 (AKI), as well as patients discharged from the hospital. Our aim was to provide insights into proteomic changes during the early stages of the disease and their association 108 with AKI and post-clinical recovery. 109

110 MATERIALS AND METHODS

111 Study Design and Population

112 This prospective cohort study was conducted at Hospital São Paulo, a tertiary 113 university hospital in São Paulo, Brazil [15]. The study was approved by the research 114 ethics committee (Process number 4.453.137), and all volunteers provided written

informed consent prior to enrolment. The study comprised adult patients (≥18 years 115 old) diagnosed with COVID-19 based on positive reverse transcriptase polymerase 116 chain reaction (RT-PCR) results from nasopharyngeal swabs. These patients were 117 admitted to the hospital wards between May 10 and September 26, 2020. This period 118 coincided with the first wave of the COVID-19 pandemic in Brazil (February 25, 2020, 119 to November 5, 2020)[16], when the predominant variants observed were B.1.1.28 120 (20-30%) and B.1.1.33 (10-35%)[16]. Patients included in the cohort had moderate 121 to severe illness, as defined by guidelines from the National Institutes of Health and 122 123 the World Health Organization [17, 18]. Exclusion criteria encompassed patients referred to outpatient clinics or admitted directly to the ICU. Among the initial 68 124 COVID-19 patients in the cohort, 17 KTRs were selected for this study (for a 125 comprehensive overview of the entire cohort, please refer to Peçanha-Pietrobom et al 126 [15]). Additionally, a control group comprised 10 KTR volunteers without COVID-19 127 symptoms (KTR controls), matched to the patient group for time since transplantation, 128 immunosuppressive therapy, sex, and age. None of the participants in this study were 129 vaccinated due to the unavailability of vaccines at the time of enrolment. 130

AKI was prospectively defined according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria [19, 20]. Baseline graft function was assessed using creatinine levels recorded three months prior to COVID-19 diagnosis, and AKI was identified based on creatinine levels at hospital admission.

135 Sample Collection

Blood samples were collected from both patients and KTR controls into ethylenediaminetetraacetic acid (EDTA)-treated tubes (BD Biosciences, San Diego, CA, USA). Plasma and peripheral blood mononuclear cells (PBMCs) were separated

using a Ficoll gradient method (Ficoll-Paque PLUS, GE Healthcare Biosciences,
Uppsala, Sweden). Plasma samples were stored at -80°C, and PBMCs were
preserved in liquid nitrogen for subsequent use.

142 Measurements

For detailed information on the proteomics experiments, data processing protocols, plasma biomarker assays, and the corresponding analysis methods, please refer to the supplementary methods in **Supplementary Material 1**.

146 Statistical Analysis

Statistical analyses were performed using R (version 4.3.0). Normality of data was 147 assessed using the Shapiro-Wilk test and Quantile-Quantile (Q-Q) plots. Non-148 normally distributed data were analyzed using the Mann-Whitney U test or the 149 150 Kruskal–Wallis test, while normally distributed data were analyzed using Welch's t-test or analysis of variance (ANOVA). For post hoc testing of non-normally distributed data, 151 Dunn's test of multiple comparisons using rank sums was employed; for normally 152 153 distributed continuous data, Tukey's post hoc test was conducted. Categorical variables were compared using the chi-square test or Fisher's exact test, as 154 appropriate. Biomarker data were log-transformed to normalize their distribution. To 155 visualize the overall differences among plasma biomarkers, principal component 156 analysis (PCA) was conducted following previously established method [21, 22]. 157 Correlation analyses were performed using Spearman's rank correlation coefficient 158 (Rho). Differences between groups were quantified using standardized mean 159 differences (SMD) [23]. 160

161

162 **Bioinformatics**

Differential protein abundance analysis was performed using the R/Bioconductor 163 164 package limma. The model was adjusted for additional covariates: age, sex, time after transplantation (months), maintenance immunosuppressive therapy (class), and 165 donor status (deceased or living). Differences in PBMC proteome profiling between 166 the two groups were detected using the empirical Bayes moderated t-statistics, and 167 Benjamini-Hochberg corrections were applied to all p-values to calculate the false 168 discovery rates (FDR). Protein set enrichment analysis (PSEA) was performed using 169 the fgsea package, with annotation information from the Reactome pathway database 170 and hallmark gene sets from MSigDB. Additionally, single-sample PSEA (ssPSEA) 171 was performed using the hacksig package and the Reactome pathway database. We 172 focused on Reactome-defined immune-related pathways implicated in the host 173 response to infection: innate immune system, adaptive immune system, cytokine 174 signaling in the immune system, hemostasis, programmed cell death, and metabolism. 175

176 **RESULTS**

177 Clinical and Epidemiological Features of the Study Participants

Seventeen kidney transplant recipients (KTRs) with COVID-19, a subset of a hospital-178 179 admitted cohort with diverse clinical outcomes[15] were analyzed in this study (Table 1). According to the KDIGO criteria for staging AKI, we observed that six patients 180 (35%) did not present with AKI (stage 0), while five (29%) were classified as stage 1, 181 three (17%) as stage 2, and three (17%) as stage 3. The mean age was 54.0 years, 182 and most were male (n = 10, 59%). The time between COVID-19 symptom onset and 183 hospital admission was 7.5 ± 4.6 days. Primary symptoms included dyspnea (n = 12, 184 71%), cough (n = 12, 71%), fever (n = 7, 41%), diarrhea (n = 7, 41%), and 185

nausea/vomiting (n = 7, 41%). Arterial hypertension was the most prevalent 186 comorbidity (n = 13, 76%). Additionally, 53% of patients required ICU admission, 41% 187 underwent mechanical ventilation, 29% required renal replacement therapy, and 41% 188 died. Among the survivors, six participated in a clinical follow-up at an average of 189 29.3 ± 5.0 days after hospital discharge (designated as Convalescent Sample 30 190 [CS30]). No significant differences were observed in demographic data, maintenance 191 192 immunosuppressive therapy class, or donor status when comparing KTRs with COVID-19 and KTR controls (Table 1). 193

Global COVID-19 Perturbation of the PBMC Proteome, Plasma Proteins, and Lymphocyte Counts in Kidney Transplant Recipients

196 A TMT--based quantitative proteomic approach combined with liquid chromatographytandem mass spectrometry (LC-MS/MS) was employed to quantify differentially 197 abundant proteins (DAPs) among KTRs. The cohort was categorized based on the 198 timing of blood sampling: patients sampled during their hospital stay (D0-wards) and 199 those sampled approximately 30 days after discharge (CS30). These groups were 200 201 compared with KTRs non-COVID-19 (KTR controls). Across seven TMT batches, a total of 2,330 proteins were identified. Focusing on proteins guantified in at least 50% 202 of samples reduced this number to 1,403 proteins, with an average of 1,242 proteins 203 per sample (Supplementary Material 1: Supplementary Figure S1). Among these 204 1,403 proteins, 363 were differentially abundant between D0-wards and KTR controls 205 (Supplementary Material 1: Supplementary Figure S2A and Supplementary 206 207 **Material 1**), while 111 showed differential abundance between CS30 and KTR controls (Supplementary Material 1: Supplementary Figure S2B and Supplementary 208 Material 3). 209

210 Reactome pathway enrichment analysis revealed that D0-wards patients exhibited alterations in 15 pathways compared with KTR controls, characterized by positive 211 normalized enrichment scores (NES) in pathways associated with interferon response, 212 innate immune system, and neutrophil degranulation. Conversely, pathways related to 213 glycolysis and glucose metabolism exhibited negative NES. Similar NES patterns were 214 observed in hallmark gene set enrichment analysis, with positive NES in pathways 215 216 related to interferon response and inflammatory processes, and negative NES in metabolism-related pathways (Figure 1A). Notably, only metabolism-related 217 218 pathways remained altered in CS30 patients (Figure 1A).

Plasma biomarker levels indicative of cytokine/inflammation and endothelial cell 219 activation were significantly elevated in D0-wards patients (Figure 1B, and 220 Supplementary Material 1: Supplementary Figure S2). Additionally, two proteins, 221 NGAL and myeloperoxidase (MPO), were identified in both plasma and PBMCs 222 (proteomics), demonstrating a positive moderate correlation (Figure 1C). 223 Furthermore, the absolute number of lymphocytes, specifically T lymphocytes 224 (CD3⁺CD45⁺), T cytotoxic (CD3⁺CD8⁺), and T helper (CD3⁺CD4⁺) were lower in D0-225 wards compared to KTR controls (Figure 1D). In contrast to admission samples, all 226 plasma biomarkers (Supplementary Material 1: Supplementary Table S1) and 227 absolute lymphocyte counts were comparable between CS30 and KTR controls 228 (Supplementary Material 1: Supplementary Table S2), suggesting a potential return 229 to a homeostatic state approximately 30 days after hospital discharge. 230

Host response associated with acute kidney injury in KTR COVID-19 patients

We compared KTR COVID-19 patients who presented with AKI (N=6) to those who did not (N=11) during ward admission. Patients with AKI presented with higher

Sequential Organ Failure Assessment (SOFA) scores (SMD: 0.90), increased C-234 Reactive Protein (CRP) levels (SMD: 0.60), and elevated creatinine levels (SMD: 1.40) 235 upon ward admission. The AKI group experienced worse outcomes, including a higher 236 rate of ICU transfers (SMD: 0.64), increased need for mechanical ventilation (SMD: 237 0.86), and greater hospital mortality (SMD: 0.86). Interestingly, creatinine showed a 238 strong positive correlation with CRP (Rho=0.50, p<0.05) and SOFA respiratory 239 240 subscores (Rho=0.68, p=0.002) (Supplementary Material 1: Supplementary Figure 241 **S4**).

242 We compared the PBMC proteomic alterations in AKI and non-AKI COVID-19 patients using ssPSEA for Reactome-defined immune-related pathways. Our analysis revealed 243 alterations in seven innate immune-related pathways, three adaptive immune system 244 pathways, and five cytokine signaling pathways in the immune system. Additionally, 245 no alterations were observed in hemostasis, while four metabolic pathways and one 246 programmed cell death pathway showed alterations (Figure 2A). Indeed, the innate 247 immune-related pathways exhibited the most differences when comparing patients 248 with AKI and non-AKI; these pathways also demonstrated a pattern of positive 249 correlation with creatinine, SOFA, and CRP levels (Figure 2B). 250

Next, we explored the differences between KTR COVID-19 patients with AKI and non-AKI based on 15 host response biomarkers reflective of two key pathophysiological domains (cytokine/inflammatory response and endothelial cell activation/procoagulant responses) in plasma obtained on admission to the wards. First, we generated domain-specific PCA plots to compare the groups (**Figure 3**). There were significant differences in plasma biomarkers grouped in the cytokine/inflammatory response domain between patients with AKI and non-AKI. We also identified a substantial

overlap in the endothelial cell activation/procoagulant responses between the AKI and
non-AKI groups (Figure 3A). The complete contribution of each biomarker to a
principal component (PC) score is depicted in Supplementary Material 1:
Supplementary Table S3.

When comparing the magnitude of individual biomarker differences expressed as 262 Hedges' g, we observed moderate to large increases in cytokine/inflammatory markers 263 among AKI patients, while endothelial cell activation/procoagulant markers showed 264 small or negligible differences (Figure 3B). Subsequently, we evaluated the absolute 265 number of total lymphocytes, which showed statistical differences when comparing the 266 KTR control and COVID-19 AKI groups (Figure 3C). We also observed differences 267 between the control and COVID-19 AKI groups for T helper cells. For T lymphocytes 268 and T cytotoxic cells, differences were found in both comparisons between the KTR 269 control vs. COVID-19 AKI groups, as well as between the KTR control vs. non-AKI 270 groups. No differences were found in the comparison between the groups for the 271 helper/cytotoxic ratio, B lymphocytes, and NK cells. Interestingly, for total lymphocytes, 272 T lymphocytes, T cytotoxic cells, and T helper cells, the AKI group consistently showed 273 lower absolute values than the non-AKI group, but with no statistical difference in the 274 pairwise comparison. 275

Previous studies suggest an increase in immature cells, such as low-density neutrophils (LDNs) or granulocytic/polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), in COVID-19 patients, which correlate with T cell suppression [24, 25]. LDNs commonly co-purify with PBMCs in various infections, enriching pathways like "neutrophil degranulation" in omics studies [26-31]. Therefore, we tested the correlation between the absolute values of T lymphocytes and the "neutrophil

degranulation" ssPSEA scores, which showed a moderate negative correlation
between T lymphocytes (Rho=-0.43, p=0.02), T helper cells (Rho=-0.45, p=0.03), and
the "neutrophil degranulation" score (Supplementary Material 1: Supplementary
Figure S5). A weak negative and not statistically significant correlation was found
between T cytotoxic cells and the "neutrophil degranulation" score (Rho=-0.35,
p=0.08).

288 **DISCUSSION**

289 In this study, we investigated KTRs infected with SARS-CoV-2 during the initial wave of the COVID-19 pandemic in São Paulo, Brazil. Based on the reported increased 290 severity of COVID-19 in KTRs [4, 5, 7-9], we aimed to investigate the changes in 291 proteomics within PBMCs in this specific population. Additionally, we explored the 292 reported immune dysregulation and endothelial cell activation/procoagulant alterations 293 in COVID-19 [10, 32, 33], particularly emphasizing the early stages of hospitalization 294 while patients are in the ward. Furthermore, we investigated the reported reductions 295 in absolute counts of lymphocytes, especially T lymphocytes and their subsets, during 296 the acute phase of COVID-19 [34, 35], with a specific focus on KTRs. 297

The proteomic response during the acute phase of COVID-19 has been widely 298 explored [28, 30, 31, 36], while the proteomic alterations within PBMCs of KTRs were 299 negligible. Our study revealed proteomic alterations linked to inflammatory/immune 300 response pathways, indicated by positive NES. Interestingly, the majority of these 301 302 pathways reverted to a status similar to that of non-COVID-19 KTRs after 30 days. This pattern aligns with our previous findings from a separate cohort of COVID-19 303 patients without KTRs [28] and is consistent with other omics reports [25, 30, 31]. 304 305 Notably, the glycolysis and glucose metabolism pathways exhibited a negative NES

306 and remained altered after 30 days. This metabolic alteration may affect immune cell function in pathogen recognition, as glycolysis plays a pivotal role in this process [37]. 307 This dysfunctional glycolysis profile shares similarities with findings from proteomic 308 studies of PBMCs from critically ill COVID-19 patients [28], transcriptomic/metabolic 309 profiling of CD14+ monocytes from patients with moderate COVID-19 [38], and single-310 cell RNA sequencing in monocytes and macrophages from severe patients with 311 312 COVID-19-associated pulmonary aspergillosis [39]. The impaired glycolysis observed in this context may serve as an indicator of the dysfunctional host response, potentially 313 314 contributing to heightened morbidity and mortality rates among KTRs.

Next, we investigated the proteomic alterations based on the presence of AKI, a 315 prevalent condition in systemic illnesses affecting a significant portion of hospitalized 316 COVID-19 patients [40]. Analysis of immune-related pathways revealed increased 317 NES in the innate immune system, complement cascade, regulated necrosis, 318 antimicrobial peptides, and neutrophil degranulation in COVID-19 AKI patients. These 319 320 results are in line with studies discussing the pathophysiology of COVID-19associated AKI, which is believed to be multifaceted [40], involving factors such as 321 local and systemic inflammatory/immune response, and activation of coagulation 322 cascades [41, 42]. This is further evidenced when examining host response 323 biomarkers, where the PCA corresponding to this cytokine/inflammatory response 324 domain clearly separates patients with AKI from those without, a distinction not 325 observed in the endothelial domain. It is noteworthy that COVID-19 pathophysiology 326 327 in KTRs remains largely unknown. While various general factors commonly encountered in critically ill patients, including mechanical ventilation, hypoxia, 328 329 hypotension, and exposure to nephrotoxic agents, are recognized contributors to

kidney injury, [41] the role of direct viral infection with renal tropism, as proposed by
some studies, remains unclear [43, 44].

332 Although no statistically significant differences were observed in lymphocyte counts between the AKI and non-AKI groups, it is likely that these disturbances were more 333 severe in the AKI group, as illustrated by the finding that absolute counts of total 334 335 lymphocytes and T helper cells were lower in the AKI group but not in the non-Aki group compared to the controls. Previous studies have demonstrated that T 336 lymphocyte counts and their subsets typically decrease during the acute phase of 337 COVID-19,[34, 35, 45]. T lymphocytes play a pivotal role in clearing the virus during 338 SARS-CoV infection [46, 47]. Interestingly, the increase in LDNs/PMN-MDSCs may 339 directly correlate with the decrease in the number of T cells [24, 25]. Despite their 340 immunosuppressive properties, LDNs/PMN-MDSCs have also been associated with 341 a pro-inflammatory phenotype, characterized by elevated levels of cytokine secretion 342 and formation of neutrophil extracellular traps [27, 48, 49]. The presence of LDNs has 343 been observed in previous studies [26, 28, 29], , and might be correlated to the severity 344 of infectious diseases [25, 30]. In fact, the AKI group is more severe than the non-AKI, 345 showing higher SOFA scores, CRP levels, and worse outcomes. This may be 346 associated with high scores for LDNs, as well as inflammatory/immune responses. 347 Our findings suggest a relationship between T-cell suppression and elevated levels of 348 LDN-related proteins in PBMCs during COVID-19, particularly in patients with AKI. 349 This association may carry important therapeutic implications for managing immune 350 dysregulation in KTRs, highlighting the need for targeted interventions aimed at 351 mitigating these immune alterations. 352

This study has some limitations. First, the sample size was relatively small, and all patients were enrolled at a single center. Additionally, the absence of a validation

cohort from another hospital in a different geographical region limits the 355 generalizability of our findings. Moreover, we did not investigate the influence of viral 356 load or the roles of virus variants on the results obtained. Our study was conducted in 357 2020, so the relevance to current variants is less clear, since SARS-CoV2 variants 358 exhibit increasing fitness, and declining pathogenicity and induced-inflammatory 359 response [50]. Furthermore, functional assays to validate glycolysis metabolism 360 361 changes and/or the potential contribution of LDNs in AKI were not conducted, which could have provided further insight into our results. Despite these limitations, our study 362 363 also has notable strengths. We investigated PBMCs, a cell type that is not often explored in COVID-19 proteomics research. Our study of KTRs infected with SARS-364 CoV-2, along with a well-established cohort of controls, provides valuable insights and 365 is relatively unexplored. Additionally, all individuals were unvaccinated, allowing for a 366 clearer assessment of proteomic alterations in the absence of vaccination. 367 Furthermore, the samples obtained in the wards and after discharge provided a 368 comprehensive understanding of cellular proteomic changes throughout the initial 369 symptoms of the disease and convalescence. 370

Future studies with larger, more diverse cohorts are needed to validate our findings and evaluate their long-term clinical implications. As a next step, we aim to explore patients with community-acquired infections, including both KTRs and non KTRs, to investigate broader mechanisms of immune dysregulation. These insights lay the groundwork for the development of targeted therapeutic interventions to address immune dysregulation in vulnerable populations, particularly kidney transplant recipients.

In summary, our study offers preliminary insights into the proteomic alterations within
 PBMCs of KTRs infected with SARS-CoV-2 during the early phase of the COVID-19

pandemic. We identified significant dysregulation in key biological pathways, 380 particularly those involved in glycolysis, glucose metabolism, and neutrophil 381 degranulation, which may reflect the heightened inflammatory state associated with 382 COVID-19 in this vulnerable population. While our findings suggest an altered immune 383 response-characterized by elevated cytokines, inflammatory mediators, and 384 decreased lymphocyte counts-these results must be interpreted cautiously due to 385 386 the small sample size. The observed association between T-cell suppression and increased levels of LDN-related proteins in AKI patients warrants further investigation, 387 388 as it may hold therapeutic implications for mitigating immune dysregulation in COVID-

389 19-infected KTRs.

Data Availability Statement

Raw and processed mass spectrometry proteomic data generated in this study are available at ProteomeXchange with the dataset identifier PXD051702.

393 Author Contributions

- Giuseppe G. F. Leite (Conceptualization; Proteomic sample preparation; Data
 curation; Formal analysis; Investigation; Methodology; Visualization; Writing original
 draft; Writing review & editing);
- Mônica Bragança Sousa (Involved in collecting the data; Writing review & editing);
- Larissa de Oliveira C. P. Rodrigues (Involved in collecting the data; Writing review & editing);
- 400 Milena Karina Colo Brunialti (Involved in collecting the data; Writing review & editing);
- 401 José Medina-Pestana Writing (Intellectual input; Writing review & editing);
- Joe M. Butler Writing (Methodology; Intellectual input; Writing review & editing);
- 403 Hessel Peters-Sengers (Methodology; Intellectual input; Writing review & editing);
- 404 Lúcio Requião-Moura (Supervision Intellectual input; Data curation; Writing original
 405 draft; Writing review & editing);
- 406 Reinaldo Salomão (Funding acquisition; Supervision Intellectual input; Data curation;
 407 Visualization; Writing original draft; Writing review & editing)

409

410 Funding

- 411 This work was funded by FAPESP (Grants 2017/21052-0 and 2020/05110-2) to R.S.
- 412 G.G.F.L. has a scholarship from FAPESP (2019/20532-3).

413 **Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

417 Acknowledgments

- The authors thank Nancy Bellei, Universidade Federal de São Paulo, for the SARS-CoV-2 PCR test; Paulo R. Abrão Ferreira, Jaquelina Sonoe Ota-Arakaki and Paula M. Peçanha-Pietrobom for the support with the selection and enrollment of patients. We thank Paolo Di Mascio and Graziella E. Ronsein for the mass spectrometry analyses performed at the Redox Proteomics Core of the Mass Spectrometry Resource at Chemistry Institute, University of São Paulo (FAPESP grant numbers 2012/12663-1 and 2016/00696-3, CEPID Redoxoma 2013/07937-8).
- 425 Supplementary material
- 426 **Supplementary material 1.** Methods, Tables, and Figures.
- 427 Supplementary material 2. List of differentially abundant proteins in between D0428 wards and KTR controls
- 429 Supplementary material 3. List of differentially abundant proteins in CS30 and KTR430 controls
- 431

433 **REFERENCES**

- Naseer S, Khalid S, Parveen S, Abbass K, Song H, Achim MV. COVID-19
 outbreak: Impact on global economy. *Front Public Health*. 2022; **10**: 1009393.
- 436 2. Squires N, Garfield R, Mohamed-Ahmed O, et al. Essential public health
 437 functions: the key to resilient health systems. *BMJ Glob Health*. 2023; 8.
- 438 3. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. *Features,*439 *Evaluation, and Treatment of Coronavirus (COVID-19)*. StatPearls Publishing,
 440 Treasure Island (FL), 2022.
- 441 4. Weiss A, Hendrickx R, Stensgaard E, Jellingsø M, Sommer MOA. Kidney
 442 Transplant and Dialysis Patients Remain at Increased Risk for Succumbing to
 443 COVID-19. *Transplantation*. 2023; **107**: 1136-8.
- 444 5. Demir E, Ucar ZA, Dheir H, et al. COVID-19 in Kidney Transplant Recipients: A
 445 Multicenter Experience from the First Two Waves of Pandemic. *BMC*446 *Nephrology*. 2022; 23: 183.
- 6. Sanders JF, Messchendorp AL, de Vries RD, et al. Antibody and T-Cell
 Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273
 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With
 a Kidney Transplant. *Clin Infect Dis.* 2023; **76**: e188-e99.
- 451 7. Medina-Pestana J, Cristelli MP, Foresto RD, Tedesco-Silva H, Requião-Moura
 452 LR. The Higher COVID-19 Fatality Rate Among Kidney Transplant Recipients
 453 Calls for Further Action. *Transplantation*. 2022; **106**: 908-10.
- Callaghan CJ, Mumford L, Curtis RMK, et al. Real-world Effectiveness of the
 Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines
 Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients.
 Transplantation. 2022; **106**: 436-46.
- 458 9. Choudhary D, Kenwar D, Sharma A, et al. Risk factors for mortality in kidney
 459 transplant recipients with COVID-19: a single centre experience and case–
 460 control study. *BMC Nephrology*. 2022; 23: 241.
- 461 10. Brunialti MKC, Leite GGF, Eburneo GS, et al. Patterns of Circulating Cytokines
 462 and Vascular Markers' Response in the Presence of COVID-19 in Kidney
 463 Transplant Recipients Compared with Non-Transplanted Patients. *Viruses*.
 464 2023; **15**: 2166.
- 11. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker
 for human acute kidney injury. *Biomark Med*. 2010; 4: 265-80.
- Requião-Moura LR, Sandes-Freitas TV, Viana LA, et al. High mortality among
 kidney transplant recipients diagnosed with coronavirus disease 2019: Results
 from the Brazilian multicenter cohort study. *PLoS One*. 2021; **16**: e0254822.
- 470 13. Gisby J, Clarke CL, Medjeral-Thomas N, et al. Longitudinal proteomic profiling
 471 of dialysis patients with COVID-19 reveals markers of severity and predictors
 472 of death. *Elife*. 2021; **10**.

- 14. Lin H, Ma X, Xiao F, et al. Identification of a special cell type as a determinant 473 of the kidney tropism of SARS-CoV-2. The FEBS Journal. 2021; 288: 5163-78. 474
- 15. Peçanha-Pietrobom PM, Leite GGF, Hunter J, et al. The clinical course of 475 hospitalized moderately ill COVID-19 patients is mirrored by routine 476 hematologic tests and influenced by renal transplantation. PLOS ONE. 2021; 477 **16**: e0258987. 478
- Zeiser FA, Donida B, da Costa CA, et al. First and second COVID-19 waves in 16. 479 480 Brazil: A cross-sectional study of patients' characteristics related to hospitalization and in-hospital mortality. The Lancet Regional Health -481 Americas. 2022; 6. 482
- 17. National Institutes of Health. COVID-19 Treatment Guidelines Panel. 483 Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 484 https://www.covid19treatmentguidelines.nih.gov/. [Accessed Dezember 15, 485 2022]. 486
- 18. World Health Organization. Clinical management of COVID-19: living guideline, 487 488 15 September 2022. 2022. https://iris.who.int/handle/10665/362783. [Accessed Dezember 15, 2022]. 489
- KDIGO AKI Work Group. KDIGO Clinical Practice Guideline for Acute Kidney 490 19. 491 Injury. Kidney Int Suppl. 2012; 2: 1-141.
- 20. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality 492 Initiative w. Acute renal failure - definition, outcome measures, animal models, 493 fluid therapy and information technology needs: the Second International 494 Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. 495 *Critical care*. 2004; **8**: R204-12. 496
- 21. Michels EHA, Appelman B, Brabander Jd, et al. Age-related changes in plasma 497 biomarkers and their association with mortality in COVID-19. European 498 499 Respiratory Journal. 2023: 2300011.
- Peters-Sengers H, Butler JM, Uhel F, et al. Source-specific host response and 22. 500 outcomes in critically ill patients with sepsis: a prospective cohort study. 501 Intensive Care Med. 2022; 48: 92-102. 502
- 23. Lin L, Aloe AM. Evaluation of various estimators for standardized mean 503 difference in meta-analysis. Stat Med. 2021; 40: 403-26. 504
- 24. Morrissey SM, Geller AE, Hu X, et al. A specific low-density neutrophil 505 population correlates with hypercoagulation and disease severity in 506 hospitalized COVID-19 patients. JCI Insight. 2021; 6. 507
- 25. Carapito R, Li R, Helms J, et al. Identification of driver genes for critical forms 508 of COVID-19 in a deeply phenotyped young patient cohort. Sci Transl Med. 509 2022; 14: eabj7521. 510
- 26. Leite GGF, Ferreira BL, Tashima AK, et al. Combined Transcriptome and 511 Leukocyte's Profiling Reveals **Up-Regulated** 512 Proteome Module of Genes/Proteins Related to Low Density Neutrophils and Impaired Transcription 513 and Translation Processes in Clinical Sepsis. Front Immunol. 2021; 12. 514

medRxiv preprint doi: https://doi.org/10.1101/2024.09.19.24313795; this version posted September 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. It is made available under a CC-BY 4.0 International license .
- 27. Eisfeld AJ, Halfmann PJ, Wendler JP, et al. Multi-platform 'Omics Analysis of 515 Human Ebola Virus Disease Pathogenesis. Cell Host Microbe. 2017; 22: 817-516 29.e8. 517
- 28. Leite GGF, Brunialti MKC, Peçanha-Pietrobom PM, et al. Understanding 518 COVID-19 progression with longitudinal peripheral blood mononuclear cell 519 proteomics: Changes in the cellular proteome over time. iScience. 2023; 26: 520 107824. 521
- 522 29. Carapito R, Li R, Helms J, et al. Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Science 523 Translational Medicine. 2022; 14: eabj7521. 524
- 30. Potts M, Fletcher-Etherington A, Nightingale K, et al. Proteomic analysis of 525 circulating immune cells identifies cellular phenotypes associated with COVID-526 19 severity. Cell Rep. 2023; 42: 112613. 527
- 31. Li J, Guo M, Tian X, et al. Virus-Host Interactome and Proteomic Survey Reveal 528 Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis. Med (N Y). 529 530 2021; **2**: 99-112.e7.
- 32. Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-531 532 19. Nat Med. 2021; 27: 1674-5.
- 33. Sims JT, Krishnan V, Chang CY, et al. Characterization of the cytokine storm 533 reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin 534 Immunol. 2021; **147**: 107-11. 535
- Cantenys-Molina S, Fernández-Cruz E, Francos P, Lopez Bernaldo de Quirós 34. 536 JC, Muñoz P, Gil-Herrera J. Lymphocyte subsets early predict mortality in a 537 large series of hospitalized COVID-19 patients in Spain. Clinical and 538 Experimental Immunology. 2020; 203: 424-32. 539
- 35. Huang M, Wang Y, Ye J, Da H, Fang S, Chen L. Dynamic changes of T-540 541 lymphocyte subsets and the correlations with 89 patients with coronavirus disease 2019 (COVID-19). Ann Transl Med. 2020; 8: 1145. 542
- 36. Gu X, Wang S, Zhang W, et al. Probing long COVID through a proteomic lens: 543 a comprehensive two-year longitudinal cohort study of hospitalised survivors. 544 eBioMedicine. 2023; 98. 545
- 37. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic 546 cells in innate immunity. Cell Res. 2015; 25: 771-84. 547
- 38. Maher AK, Burnham KL, Jones EM, et al. Transcriptional reprogramming from 548 innate immune functions to a pro-thrombotic signature by monocytes in COVID-549 19. Nat Commun. 2022; 13: 7947. 550
- 39. Feys S, Vanmassenhove S, Kraisin S, et al. Lower respiratory tract single-cell 551 552 RNA sequencing and neutrophil extracellular trap profiling of COVID-19pulmonary associated aspergillosis: а single centre. retrospective, 553 observational study. Lancet Microbe. 2024; 5: e247-e60. 554
- 40. Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of Acute Kidney Injury and 555 Longitudinal Kidney Function After Hospital Discharge Among Patients With 556 and Without COVID-19. JAMA Netw Open. 2021; 4: e211095. 557

- 41. Legrand M, Bell S, Forni L, et al. Pathophysiology of COVID-19-associated 558 acute kidney injury. Nat Rev Nephrol. 2021; 17: 751-64. 559
- 42. Wu H, Larsen CP, Hernandez-Arroyo CF, et al. AKI and Collapsing 560 Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype. 561 J Am Soc Nephrol. 2020; **31**: 1688-95. 562
- 43. Miller SE, Brealey JK. Visualization of putative coronavirus in kidney. *Kidney* 563 Int. 2020; 98: 231-2. 564
- 565 44. Delorey TM, Ziegler CGK, Heimberg G, et al. COVID-19 tissue atlases reveal 566 SARS-CoV-2 pathology and cellular targets. *Nature*. 2021; **595**: 107-13.
- Iannetta M, Buccisano F, Fraboni D, et al. Baseline T-lymphocyte subset 45. 567 absolute counts can predict both outcome and severity in SARS-CoV-2 infected 568 patients: a single center study. Scientific Reports. 2021; 11: 12762. 569
- Zhao J, Zhao J, Van Rooijen N, Perlman S. Evasion by stealth: inefficient 570 46. immune activation underlies poor T cell response and severe disease in SARS-571 CoV-infected mice. PLoS Pathog. 2009; 5: e1000636. 572
- 47. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With 573 Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71: 762-574 575 8.
- Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P. Neutrophil Diversity in 48. 576 Health and Disease. Trends Immunol. 2019; 40: 565-83. 577
- 49. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of 578 neutrophils in systemic autoimmunity. Semin Immunopathol. 2013; 35: 455-63. 579
- 50. Barh D, Tiwari S, Rodrigues Gomes LG, et al. SARS-CoV-2 Variants Show a 580 581 Gradual Declining Pathogenicity and Pro-Inflammatory Cytokine Stimulation, an Increasing Antigenic and Anti-Inflammatory Cytokine Induction, and Rising 582 Structural Protein Instability: A Minimal Number Genome-Based Approach. 583 Inflammation. 2023; 46: 297-312. 584
- 585
- 586
- 587
- 588
- 589
- 590
- 591
- 592
- 593

- Tables

Table 1. Baseline characteristics and clinical outcomes of KTR COVID-19 patients at ward admission and KTR Controls

	D0-Wards , (N=17) ¹	KTR Controls, (N=10) ¹	<i>p</i> -value
Demographics			
Age years	54.1 (11.1)	55.1 (6.3)	0.91
Male sex	10 (59%)	6 (60%)	0.96
Time after transplantation (months)	89.6 (90.6)	118.2 (119.4)	0.72
BMI	25.6 (4.1)		
Admission type, wards	17 (100%)		
Maintenance immunosuppress	ive therapy (class)		0.09
Aza/MPA+Pred	2 (12%)	0 (0%)	
CNI+Aza/MPA+Pred	15 (88%)	8 (80%)	
CNI+mTORi+Pred	0 (0%)	2 (20%)	
Donor information	. ,	/	>0.99
Deceased donor	12 (71%)	7 (70%)	
Living donor	5 (29%)	3 (30%)	
AKI stages (KDIGO criteria)			
0	6 (35%)		
1	5 (29%)		
2	3 (17%)		
3	3 (17%)		
Comorbidity	· ·		
Charlson Index	3.9 (1.5)		
Renal Disease Moderate or Severe	17 (100%)		
Diabetes	6 (35%)		
Hypertension	13 (76%)		
Obesity	1 (5.9%)		
Disease severity on admission			
SOFA score	2.9 (1.8)		
Temperature °C	36.8 (0.9)		
Heart rate	85.6 (13.4)		
Respiratory rate	23.2 (3.7)		
Saturation O2	92.9 (3.2)		
Respiratory support			
No	10 (59%)		
Non-rebreather masks	2 (12%)		

Supplemental oxygen	5 (29%)	
Symptoms on admission		
Symptoms to wards (days)	7.5 (4.6)	
Fever	7 (41%)	
Cough	12 (71%)	
Myalgia	6 (35%)	
Fatigue/Anxiety	2 (12%)	
Dyspnea	12 (71%)	
Headache	4 (24%)	
Nausea/Vomiting	7 (41%)	
Anosmia	3 (18%)	
Dysgeusia	3 (18%)	
Diarrhea	7 (41%)	
Laboratory on admission	, , , , , , , , , , , , , , , , ,	
Hemoglobin, g/dL	12.3 (1.5)	
Hematocrit (%)	37.6 (3.9)	
Red Cell Distribution Width, (%)	13.9 (1.4)	
Neutrophils, cells/µl	5,120.1 (2,128.5)	
_ymphocytes, cells/µl	765.2 (456.3)	
Monocytes, cells/µl	392.6 (263.9)	
	196,705.9 [′]	
Platelets, cells/µl	(69,058.6)	
Creatinine, mg/dL	2.1 (1.4)	
C-Reactive Protein, mg/L	103.2 (50.7)	
Ͻ-dimer, μg/mL FEU	1.2 (0.7)	
Dutcomes		
Fransferred to ICU	9 (53%)	
Mechanical ventilation	7 (41%)	
Renal replacement therapy	5 (29%)	
Days in ICU	19.6 (13.3)	
Death in ICU (30-day mortality)	7 (41%)	
Continuous variables are shown a	s mean ± SD. Categori	cal variables are shown as absolute
numbers (percentages). Abbreviatio	on: Aza = azathioprine	, CNI = Calcineurin inhibitors, MPS
myconhenolate acid Pred = n	rednisone mTORi =	mammalian target of ranamycin
		mammanan target of raparityon
nhibitors.		

Table 2. Demography, comorbidities, clinical and laboratory admission data, and

outcomes stratified according to the presence of acute kidney injury

Characteristic	AKI (N=11) ¹	non-AKI (N=6) ¹	SMD			
Demographics						
Age years	51.7 (12.4)	58.2 (7.4)	-0.56			
Male sex	7 (64%)	3 (50%)	0.13			
BMI	24.8 (4.4)	26.9 (3.7)	-0.53			
Comorbidity						
Charlson Index	3.8 (1.7)	4.0 (1.4)	-0.12			
Diabetes	3 (27%)	3 (50%)	-0.48			
Hypertension	7 (64%)	6 (100%)	-1.07			
Obesity	0 (0%)	1 (17%)	-0.63			
Disease severity on admiss	sion					
SOFA score	3.5 (1.8)	2.0 (1.4)	0.90			
Temperature °C	36.9 (1.0)	36.6 (0.6)	0.42			
Heart rate	83.8 (15.1)	88.8 (9.9)	-0.39			
Respiratory rate	22.9 (4.6)	23.8 (1.3)	0.27			
Saturation O2	92.8 (3.6)	93.0 (2.5)	-0.06			
Respiratory support	4 (36.4%)	3 (50.0%)	0.28			
Symptoms on admission						
Symptoms to wards (days)	8.1 (5.5)	6.5 (2.1)	0.38			
Fever	5 (45%)	2 (33%)	0.25			
Cough	7 (64%)	5 (83%)	-0.46			
Myalgia	5 (45%)	1 (17%)	0.66			
Fatigue/Anxiety	1 (9.1%)	1 (17%)	-0.23			
Dyspnea	7 (64%)	5 (83%)	0.46			
Headache	2 (18%)	2 (33%)	0.35			
Vomiting/nausea	4 (36%)	3 (50%)	0.28			
Anosmia	1 (9.1%)	2 (33%)	0.62			
Dysgeusia	1 (9.1%)	2 (33%)	0.62			
Diarrhea	4 (36%)	3 (50%)	0.28			
Laboratory on admission						
Hemoglobin, g/dL	12.1 (1.5)	12.8 (1.4)	-0.46			
Hematocrit (%)	37.1 (4.0)	38.7 (3.9)	-0.40			
RDW, (%)	14.0 (1.7)	13.6 (0.8)	0.35			
Neutrophils, cells/µl	4,846.5 (1,646.6)	5,621.5 (2,934.0)	-0.33			
Lymphocytes, cells/µl	677.3 (448.4)	926.5 (464.8)	-0.55			
Monocytes, cells/µl	393.8 (295.1)	390.3 (220.7)	0.01			
Platelets, cells/ul	206,090.9	179,500.0	0.40			
······································	(75,525.4)	(57,479.6)				

perpetuity. It is made available under a CC-BY 4.0 International license .

2	Э	۵
υ	э	υ.

637

638

639 Figure legends

Figure 1. Comprehensive assessment of COVID-19 impact on PBMC proteome, plasma proteins, and lymphocyte counts.

Description Figure 1: A) Protein set enrichment analysis (PSEA) demonstrating 642 protein perturbations in D0-wards patients (n=17) versus KTR controls (n=10), and 643 CS30 patients (n=6) versus KTR controls. Circle size represents the -log10(BH-644 645 adjusted p-value), while color denotes the normalized enrichment score (NES). Red indicates increased NES, and blue indicates decreased NES. B) Heatmap showing 646 the magnitude of biomarker differences between D0-wards patients and KTR controls, 647 quantified using Hedges' g. The red gradient highlights elevated biomarker levels in 648 D0-wards patients. (For pairwise comparisons, see Figure S3). C) Scatter plot 649 illustrating Spearman's rank correlation coefficients (Rho) between myeloperoxidase 650 651 (MPO) and neutrophil gelatinase-associated lipocalin (NGAL) abundances in plasma and PBMCs (proteomic data). P-values are BH-adjusted, and **D**) Box plot comparing 652 653 absolute lymphocyte counts between D0-wards COVID-19 patients and KTR controls. Statistical analyses were performed using Welch's t-test, with significance levels 654 indicated by $**p \le 0.01$ and $***p \le 0.001$. 655

656

Figure 2. Alterations in immune-related pathways in COVID-19 patients stratified according to the presence of acute kidney injury.

Description Figure 2: A) Single-sample protein set enrichment analysis (ssPSEA) 659 was performed on D0-wards COVID-19 patients stratified by the presence of acute 660 kidney injury (AKI, n=11) and non-AKI (n=6), as well as KTR controls (n=10). The figure 661 presents only immune-related pathways that showed significant differences between 662 the groups. Statistical analyses were conducted using ANOVA with Tukey's post-hoc 663 test, corrected by the Benjamini-Hochberg method. Significance is indicated as 664 follows: *p \leq 0.05, **p \leq 0.01, ***p \leq 0.001, and ****p \leq 0.0001, and **B**) Heatmap 665 showing Spearman's rank correlation coefficients (Rho) between the sequential organ 666 failure assessment (SOFA) score, C-reactive protein (CRP) levels, creatinine levels, 667 and ssPSEA pathway scores in D0-wards COVID-19 patients (n=17). Abbreviations: 668 TLR cascades: Toll-like receptor cascades, NLR signaling: Nucleotide-binding 669 domain. leucine rich repeat containing receptor signaling pathway, TCR signaling: T 670 cell receptor signaling, Immunoregulatory between Lymphoid & non-Lymphoid cell: 671 672 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell, Rap1 signaling: Ras-proximate-1 signaling and Metabolism of vit and cofactors: Metabolism 673 674 of vitamins and cofactors.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 675
- 676
- 677

Figure 3. Host response biomarkers and lymphocyte count alterations in COVID 19 patients stratified according to the presence of acute kidney injury

680 **Description Figure 3: A)** Principal component analysis of cytokine/inflammatory 681 responses and endothelial cell activation/procoagulant responses. The X-axis label shows the percentage of explained variance on principal component 1, while the Y-682 axis label shows the percentage of explained variance on principal component 2. The 683 ellipse indicates the central 25% of the groups. The arrows indicate the direction (arrow 684 orientation) and strength (arrow length) of the correlation between each biomarker and 685 the PCs. The complete contribution of each biomarker to a PC score is depicted in 686 Supplementary Table S3. B) Heatmap representing the Hedges' g effect size between 687 the AKI COVID-19 group compared with the non-AKI group (for pairwise comparison 688 see Supplementary Table S4), and C) Box plot illustrating differences in lymphocyte 689 absolute counts between D0-wards COVID-19 patients stratified according to the 690 presence of acute kidney injury (AKI, n=11, and non-AKI, n=06) and KTR controls 691 (n=10). Statistical analyses were performed using the ANOVA test with Tukey post-692 hoc test corrected by the Benjamini-Hochberg method. * Tukey post-hoc test $p \le 0.05$ 693 and ** $p \le 0.01$. Abbreviations: IL: interleukin, GDF: growth/differentiation factor, G-694 CSF: granulocyte-colony stimulating factor, IFN: interferon, CRP: C-Reactive Protein, 695 NGAL: neutrophil gelatinase-associated lipocalin, MPO: Myeloperoxidase, ADAMTS-696 13: ADAM metallopeptidase with thrombospondin type 1 motif 13, sP-selectin: Soluble 697 platelet selectin, sVCAM-1: Serum vascular cell adhesion molecule-1 and sICAM-1: 698 Soluble Intercellular Adhesion Molecule-1. 699







1.0

ssPSEA score

0.0

1.0

ssPSEA score

0.0

Groups

KTR controls









Gluconeogenesis







COVID-19 AKI



ماد ماد

**

NLR signaling

1.0-

0.5

0.0

1.0

0.5







CRP



COVID-19 non-AKI

1.0

0.5

0.0

